NEW YORK (GenomeWeb News) – Protea Biosciences today announced a worldwide licensing agreement with George Washington University for mass spectrometry-based technology.
The technology, called Laser Ablation Electrospray Ionization, or LAESI, can directly identify proteins, peptides, lipids, and metabolites in biological samples, including tissue, blood, urine, and single cells, Protea said in a statement.
Developed in the laboratory of Akos Vertes, a professor of chemistry, biochemistry and molecular biology at GWU and founder and co-director of the W.M. Keck Institute for Proteomics Technology, LAESI allows an analysis to be done in less than two seconds and enables 3-dimension mapping of biomolecules through depth profiling and lateral imaging, the Morgantown, W. Va.-based company added.
Little or no sample preparation is required, Protea said.
The technology is described in a study published yesterday in PLoS One, in which Vertes and his colleagues identified virally infected human cells.
Protea and the Vertes lab will now develop instrumentation and software for the technology, it said. Terms of the agreement were not disclosed.
"We foresee a broad range of commercial applications in chemical and biological research, surgical pathology, clinical diagnostics, chemical and biological defense, forensics, agriculture, and many other fields," Steve Turner, CEO of Protea, said.